



Alertgy has developed **DeepGlucoband**<sup>®</sup>, a wearable Non-Invasive Continuous Blood Glucose Monitor (NICBGM) wristband that can fit on smartwatch or use smartphone

### Intellectual Property

US Patent 62788197

- Dielectric material TS
- Circuit topology/ASIC
- Algorithms/AI TS

### Financing Status

Secured: \$3.5M total  
 Seed Round: \$1.2M  
 Bridge Round: \$2.3 M  
 Series A: \$10 M target

### Traction:

- Developed Gen 1 MVP
- Completed 2 Clinical Trials
- Created Gen 2 MVP
- Developed Smart Phones Apps
- Developed IoT AI platform
- Won 440K SEMI Flex Grant
- Successfully completed grant

### Series A \$10M (Q2 '21) UoF:

- FDA Trails Gen 2 product
- Start IMEC chip Gen 3
- Key Hires
- Onboard Key Partners
- FDA Approval Gen2

### Clinical Study Completed

US: Clinical Site 1 : Q1 '20  
 US: Clinical Site 2 : Q2 '20

### Regulatory

FDA and / or C Mark approvals by Q4 '22

**DeepGlucoband**<sup>®</sup>, detects and monitors blood glucose levels without any invasive probes or sensors, alerting patient, family, and caregivers via a smartphone link and alarm capability. Key competitive features:

- 100% non-invasive, pain-free diabetes management using dielectric spectroscopy
- Comprehensive 24/7 real-time, instantaneous alerts
- Continuous blood glucose reading, with no lag time
- Proprietary dielectric sensor, circuit topology/ASIC and algorithms/AI
- DeepGlucoband's non-invasive technology has no real direct competition

### Diabetes is a Growing Global Epidemic

- Approximately 500M diabetics worldwide, growing to 700M by 2045
- 1/3 of diabetics are unaware they diabetic and are at risk (120M worldwide)
- Noncompliant Diabetics make up 1/3 of all hospital admissions with an average stay of 1 week because they refuse to use existing glucometers
- Approximately 2B borderline diabetics worldwide

### Competitive Landscape

- 40-year-old finger prick & test strip glucometers no one wants to use
- Continuous Glucose Monitoring (CGM) competitors use embedded chemical reaction-based or optical sensors that invasively test only interstitial fluid and not real blood glucose levels and are expensive to use.

### Business Model

- License Technology for licensing fees and royalties, SAAS monthly subscription for IOT AI analytics, reporting and alerting services
- Alertgy's SAAS subscription pricing will be below existing use prices for CGMs
- At a 15% US or European Market penetration of 6M users target recurring revenue of \$1B+ is achievable
- Addresses all diabetic markets including borderline diabetics

### Management

Marc Rippen CEO former Director Engineering SRI, John Hubert COO principal Microelectronics Engineer Lockheed Martin, Corporate Board with Dr. John Burd, Founder of Dexcom, See [www.alertgy.com](http://www.alertgy.com) for details on world class team.

### Projected Revenues (Millions)

	2020	2021	2022	2023	2024
Revenue	\$0	\$0	\$35	\$123	\$210
Operating Costs	\$8	\$12	\$9	\$15	\$21
EBITDA	(\$8)	(\$12)	\$15	\$69	\$123